spondylometaphyseal dysplasia
Recently Published Documents


TOTAL DOCUMENTS

112
(FIVE YEARS 25)

H-INDEX

15
(FIVE YEARS 1)

Author(s):  
Vykuntaraju K. Gowda ◽  
Varunvenkat M. Srinivasan ◽  
Varsha M. Reddy ◽  
Dhananjaya K. Vamyanmane ◽  
Sanjay K. Shivappa ◽  
...  

AbstractTransient receptor potential vanilloid 4 channel (TRPV4) gene mutations have been described in skeletal system and peripheral nervous system pathology. The case described here is a 9-year-old male child patient, born to a nonconsanguineous marriage with normal birth history who had difficulty in walking and stiffness of joints for the last 7 years, and progressive weakness of all four limbs and urine incontinence for 1 year following falls. Physical examination showed below-average weight and height and short trunk. Musculoskeletal examination revealed bony prominence bilaterally in the knee joints and contractures in knee and elbow joints with brachydactyly; muscle tone was increased, with brisk deep tendon reflexes. Skeletal survey showed platyspondyly with anterior beaking with metaphyseal dysplasia. Magnetic resonance imaging of the spine revealed atlantoaxial instability with hyperintense signal changes at a cervicomedullary junction and upper cervical cord with thinning and spinal canal stenosis suggestive of compressive myelopathy with platyspondyly and anterior beaking of the spine at cervical, thoracic and lumbar vertebrae. Exome sequencing revealed a heterozygous de novo variant c.2389G > A in exon 15 of TRPV4, which results in the amino acid substitution p.Glu797Lys in the encoded protein. The characteristics observed indicated spondylometaphyseal dysplasia, Kozlowski type (SMD-K). The child underwent surgical intervention for compressive myelopathy by reduction of atlantoaxial dislocation with C1 lateral mass and C2 pars fusion using rib graft and fixation using screws and rods. To conclude, for any child presenting with progressive kyphoscoliosis, short stature, platyspondyly, and metaphyseal changes, a diagnosis of SMD-K should be considered and the patient and family should be advised to avoid spinal injuries.


2021 ◽  
Author(s):  
Stefan Kotschi ◽  
Anna Jung ◽  
Nienke Willemsen ◽  
Anahita Ofoghi ◽  
Bettina Proneth ◽  
...  

Ferroptosis continues to emerge as a novel modality of cell death with important therapeutic implications for a variety of diseases, most notably cancer and degenerative diseases. While susceptibility, initiation, and execution of ferroptosis have been linked to reprogramming of cellular lipid metabolism, imbalances in iron-redox homeostasis, and aberrant mitochondrial respiration, the detailed mechanisms of ferroptosis are still insufficiently well understood. Here we show that diminished proteasome function is a new mechanistic feature of ferroptosis. The transcription factor nuclear factor erythroid-2, like-1 (NFE2L1) protects from ferroptosis by sustaining proteasomal activity. In cellular systems, loss of NFE2L1 reduced cellular viability after the induction of both chemically and genetically induced ferroptosis, which was linked to the regulation of proteasomal activity under these conditions. Importantly, this was reproduced in a Sedaghatian-type Spondylometaphyseal Dysplasia (SSMD) patient-derived cell line carrying mutated glutathione peroxidase-4 (GPX4), a critical regulator of ferroptosis. Also, reduced proteasomal activity was associated with ferroptosis in Gpx4-deficient mice. In a mouse model for genetic Nfe2l1 deficiency, we observed brown adipose tissue (BAT) involution, hyperubiquitination of ferroptosis regulators, including the GPX4 pathway, and other hallmarks of ferroptosis. Our data highlight the relevance of the NFE2L1-proteasome pathway in ferroptosis. Manipulation of NFE2L1 activity might enhance ferroptosis-inducing cancer therapies as well as protect from aberrant ferroptosis in neurodegeneration, general metabolism, and beyond.


Author(s):  
Francisco Cammarata-Scalisi ◽  
Uta Matysiak ◽  
Colin E. Willoughby ◽  
Gunda Ruzaike ◽  
Antonio Cárdenas Tadich ◽  
...  

AbstractSpondylometaphyseal dysplasia Algerian type (MIM no.: 184253) is an uncommon autosomal dominant skeletal dysplasia caused by heterozygous mutations in the COL2A1 gene (MIM no.: 120140). In this case based review, we reported a 5-year-old boy with short stature, severe dorsolumbar scoliosis, lumbar hyperlordosis, short trunk, and severe genu valgum. Radiological examination showed platyspondyly, irregular metaphyseal radiolucencies intermingled with radiodensities, and corner fractures. The patient has a c.3275G > A; p.Gly1092Asp mutation in exon 47 of the COL2A1 gene and a variant of unknown significance in c.1366–13C > A in intron 21. This latter sequence variant could partially or completely disrupt the natural splice acceptor site of intron 21/exon 22 in the COL2A1 gene leading to a potential modification of the phenotypic severity.


Author(s):  
Dorian Cheff ◽  
Alysson Muotri ◽  
Brent Stockwell ◽  
Edward Schmidt ◽  
Qitao Ran ◽  
...  

Background: Extremely rare progressive diseases like Sedaghatian-type Spondylometaphyseal Dysplasia (SSMD) can be neonatally lethal and therefore go undiagnosed or are difficult to treat. Recent sequencing efforts have linked this disease to mutations in GPX4, with consequences in the resulting enzyme, glutathione peroxidase 4. This offers potential diagnostic and therapeutic avenues for those suffering from this disease, though the steps toward these treatments is often convoluted, expensive, and time-consuming. Main body: The CureGPX4 organization was developed to promote awareness of GPX4-related diseases like SSMD, as well as support research that could lead to essential therapeutics for patients. We provide an overview of the 21 published SSMD cases and have compiled additional sequencing data for four previously unpublished individuals to illustrate the genetic component of SSMD, and the role of sequencing data in diagnosis. We outline in detail the steps CureGPX4 has taken to reach milestones of team creation, disease understanding, drug repurposing, and design of future studies. Conclusion: The primary aim of this review is to provide a roadmap for therapy development for rare, ultra-rare, and difficult to diagnose diseases, as well as increase awareness of the genetic component of SSMD. This work will offer a better understanding of GPx4-related diseases, and help guide researchers, clinicians, and patients interested in other rare diseases find a path towards treatments.


Author(s):  
Katharine Edgerley ◽  
Angela Barnicoat ◽  
Amaka C. Offiah ◽  
Alistair D. Calder ◽  
Kshitij Mankad ◽  
...  

2020 ◽  
Author(s):  
Nana E. Mensah ◽  
Ataf H. Sabir ◽  
Andrew Bond ◽  
Wendy Roworth ◽  
Melita Irving ◽  
...  

AbstractA pressing challenge for genomic medicine services is to increase the diagnostic rate of molecular testing. Reanalysis of genomic data can increase the diagnostic yield of molecular testing for rare diseases by 5.9-47% and novel gene-disease associations are often cited as the catalyst for significant findings. However, clinical services lack adequate resources to conduct routine reanalysis for unresolved cases. To determine whether an automated application could lead to new diagnoses and streamline routine reanalysis, we developed TierUp. TierUp identifies new gene-disease associations with implications for unresolved rare disease cases recruited to the 100,000 Genomes Project. TierUp streams data from the public PanelApp database to enable routine, up-to-date reanalyses. When applied to 948 undiagnosed rare disease cases, TierUp highlighted 410 high and moderate impact variants in under 77 minutes, reducing the burden of variants for review with this reanalysis strategy by 99%. Ongoing variant interpretation has produced five follow-up clinical reports, including a molecular diagnosis of a rare form of spondylometaphyseal dysplasia. We recommend that clinical services leverage bioinformatics expertise to develop automated reanalysis tools. Additionally, we highlight the need for studies focused on the ethical, legal and health economics considerations raised by automated reanalysis tools.


Sign in / Sign up

Export Citation Format

Share Document